Literature DB >> 16218800

Seminal reservoirs during an HIV type 1 eradication trial.

Giuseppe Nunnari1, Daniela Leto, Julie Sullivan, Yan Xu, Ketti E Mehlman, Joseph Kulkosky, Roger J Pomerantz.   

Abstract

Despite dramatic reduction of the levels of human immunodeficiency virus type I (HIV-1) virions in blood and seminal plasma of infected patients, highly active antiretroviral therapy (HAART) does not eradicate HIV-1. Three patients, with less than 50 copies/ml of plasma viral RNA, were enrolled in this eradication protocol. Didanosine (DDI) and hydroxyurea (HU) were added to their baseline HAART and after a month of therapy, low dose OKT3, followed by a 2-week course of interleukin 2 (IL-2), was administrated. All antiretroviral therapy was then interrupted and the three patients developed viral rebound in the peripheral blood. The V3 loop region of the HIV-1 gp120 from cell-free viral RNA and proviral DNA in blood and seminal compartments was sequenced in one patient. The two major viral isolates in semen cells were macrophage- tropic (R5) and dual-tropic (R5X4), and these isolates were also present in the PBMCs. Six months after the viral rebound, we demonstrated a shift toward dual tropism in semen cell-associated HIV-1 proviral DNA, with the first appearance of a T-lymphotropic (X4) provirus solely in this compartment. The virus responsible for the blood plasma viral rebound was never found in the semen microenvironment. This study suggests viral compartmentalization of the semen microenvironment after an intensification and stimulatory HIV-1 eradication protocol, with evidence of viral evolution.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16218800     DOI: 10.1089/aid.2005.21.768

Source DB:  PubMed          Journal:  AIDS Res Hum Retroviruses        ISSN: 0889-2229            Impact factor:   2.205


  9 in total

1.  Promising Role of Toll-Like Receptor 8 Agonist in Concert with Prostratin for Activation of Silent HIV.

Authors:  M A Rochat; E Schlaepfer; R F Speck
Journal:  J Virol       Date:  2017-01-31       Impact factor: 5.103

Review 2.  The complexity of HIV persistence and pathogenesis in the lung under antiretroviral therapy: challenges beyond AIDS.

Authors:  Sharilyn Almodovar
Journal:  Viral Immunol       Date:  2014-05-05       Impact factor: 2.257

Review 3.  The spreading of HIV-1 infection in the human organism is caused by fractalkine trafficking of the infected lymphocytes--a review, hypothesis and implications for treatment.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2007-04       Impact factor: 2.332

Review 4.  Cellular reservoirs of HIV-1 and their role in viral persistence.

Authors:  Aikaterini Alexaki; Yujie Liu; Brian Wigdahl
Journal:  Curr HIV Res       Date:  2008-09       Impact factor: 1.581

Review 5.  Molecular control of HIV-1 postintegration latency: implications for the development of new therapeutic strategies.

Authors:  Laurence Colin; Carine Van Lint
Journal:  Retrovirology       Date:  2009-12-04       Impact factor: 4.602

6.  Differential extracellular, but similar intracellular, disposition of two tenofovir formulations in the male genital tract.

Authors:  Julie B Dumond; Stephen A Greene; Heather M A Prince; Jingxian Chen; Brian M Maas; Craig Sykes; Amanda P Schauer; Kimberly H Blake; Julie A E Nelson; Cynthia L Gay; Angela D M Kashuba; Myron S Cohen
Journal:  Antivir Ther       Date:  2019

7.  Molecular Understanding of HIV-1 Latency.

Authors:  W Abbas; G Herbein
Journal:  Adv Virol       Date:  2012-04-04

Review 8.  HIV RNA suppression and immune restoration: can we do better?

Authors:  Marilia Rita Pinzone; Michelino Di Rosa; Bruno Cacopardo; Giuseppe Nunnari
Journal:  Clin Dev Immunol       Date:  2012-03-25

Review 9.  Head and neck squamous cell carcinoma and its correlation with human papillomavirus in people living with HIV: a systematic review.

Authors:  Manuela Ceccarelli; Emmanuele Venanzi Rullo; Alessio Facciolà; Giordano Madeddu; Bruno Cacopardo; Rosaria Taibi; Francesco D'Aleo; Marilia Rita Pinzone; Isa Picerno; Michele di Rosa; Giuseppa Visalli; Fabrizio Condorelli; Giuseppe Nunnari; Giovanni Francesco Pellicanò
Journal:  Oncotarget       Date:  2018-03-30
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.